Urol. praxi, 2014; 15(1): 18-21

Permanent implantation of radioactive seeds 125I in the prostate cancer treatment

MUDr.Branislav Obšitník, PhD., MUDr.Alžbeta Molnárová, MUDr.Pavol Lukačko, Mgr.Jozef Grežďo, PhD., RNDr.Kristína Poláková, PhD., MUDr.Ľuboš Bezák &dagger,
Onkologický ústav svätej Alžbety, Bratislava

Transperineal permanent implantation of radioactive seeds 125I – LDR (low dose rate) brachytherapy is according to actual guidelines for

prostate cancer treatment together with radical prostatectomy and external beam radiotherapy applicable as one of radical treatment

options (with curative intent) for men with localized low and intermediate risk prostate cancer. It´s effectiveness and low morbidity,

together with high probability for preservation of urinary continence and preservation of erectile functionare including brachytherapy

into the standard treatment options. This method is in Slovakia available from 2007 and clinical experience just confirm expectations

(until now 453 patients). Due to continuous technological development brachytherapy of prostate cancer can expect promising evolution

also in the future.

cancer treatment.

Keywords: prostate cancer, permanent implantation of radioactive seeds, brachytherapy of prostate cancer, LDR brachytherapy, prostate

Published: February 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Obšitník B, Molnárová A, Lukačko P, Grežďo J, Poláková K, Bezák &dagger Ľ. Permanent implantation of radioactive seeds 125I in the prostate cancer treatment. Urol. praxi. 2014;15(1):18-21.
Download citation

References

  1. Heidenreich A, et al. EUA Guidelines Prostate cancer 2013; European Association of Urology 2013, http://www.uroweb.org/gls/pdf/09_Prostate_Cancer_LR.pdf.
  2. Holm HH. The history of interstitial brachytherapy of prostatic cancer. Semin Surg Oncol. 1997 Nov-Dec; 13 (6): 431-437. Go to original source... Go to PubMed...
  3. Morton G. The best method for dose escalation: Prostate brachytherapy. Can Urol Assoc J. 2012 June; 6 (3): 196-198. doi: 10.5489/cuaj.12121. Go to original source... Go to PubMed...
  4. Doggett S. History and delopment of brachytherapy. http://www.nocancer.com/immunohistochemistry-evaluations-for-prostate-cancer.
  5. Watanabe H, Igari D, Tanahashi Y, Harada K, Saitoh M. Transrectal ultrasonotomography of the prostate. J Urol. 1975 Nov; 114 (5): 734-739. Go to original source... Go to PubMed...
  6. Molnárová A. Rádioterapia karcinómu prostaty. Trendy v urológii. 2007; 02/03:03-09.
  7. Prostate cancer diagnosis and treatment. Full Guideline February 2008 Developed for NICE by the National Collaborating Centre for Cancer. http://www.nice.org.uk/nicemedia/pdf/cg58fullguideline.pdf.
  8. Merrick GS, Butler WM, Galbreath RW, et al. Biochemical outcome for hormone naive patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy. Urology 2002 Jul; 60 (1): 98-103. http://www.ncbi.nlm.nih.gov/pubmed/12100932. Go to original source... Go to PubMed...
  9. Grimm P, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. 2012 BJU INTERNATIONAL |109, SUPPLEMENT 1, 22-29. Go to original source... Go to PubMed...
  10. Conroy R, et al. Multi-institutional outcomes following LDR brachytherapy in patients with higher-risk prostate cancer. J Clin Oncol 30; 2012 (suppl 5; abstr 238). Go to original source...




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.